+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs Used for Treating Primary Aldosteronism Market by Molecule, Route Of Administration, Line Of Therapy, Formulation, Distribution Channel - Global Forecast to 2030- Product Image
Drugs Used for Treating Primary Aldosteronism Market by Molecule, Route Of Administration, Line Of Therapy, Formulation, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Drugs Used for Treating Primary Aldosteronism Market by Molecule, Route Of Administration, Line Of Therapy, Formulation, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081445
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Setting the Stage for Emerging Primary Aldosteronism Therapies

Innovations in pharmacotherapy have fundamentally reshaped the management of primary aldosteronism over recent years. As a condition defined by excessive aldosterone production leading to hypertension and electrolyte imbalance, the demand for targeted drug therapies has intensified. Clinicians and researchers alike have directed efforts toward refining mineralocorticoid receptor antagonists, optimizing patient outcomes, and minimizing adverse effects. In parallel, regulatory frameworks and health technology assessments have evolved to accommodate novel molecules and expanding indications, underscoring the urgency for a comprehensive understanding of this dynamic therapeutic segment.

This executive summary delves into the current state of drugs used for treating primary aldosteronism, synthesizing critical developments across the pipeline and marketed products. By examining transformative shifts within the therapeutic landscape, assessing the repercussions of US tariff adjustments, and exploring segmentation nuances, this analysis equips decision-makers with a panoramic view of opportunities and challenges. Grounded in rigorous methodology and enriched by regional and competitive insights, the report lays the foundation for data-driven strategies in a field that promises to redefine hypertension management.

Redefining Treatment Protocols through Innovative Pharmacological Advances

The therapeutic landscape for primary aldosteronism has witnessed transformative shifts driven by molecular innovation and precision medicine strategies. Traditional reliance on spironolactone has given way to the emergence of eplerenone, which offers enhanced selectivity and a more favorable safety profile. Most recently, finerenone has entered clinical practice, boasting superior receptor affinity and reduced off-target effects. These molecular advances have catalyzed a paradigm shift, enabling clinicians to tailor treatment regimens with unprecedented specificity and efficacy.

Moreover, the integration of novel biomarkers and imaging techniques has sharpened diagnostic accuracy, facilitating earlier intervention and a more nuanced understanding of disease subtypes. Advances in genomics have uncovered distinct aldosterone-producing adenoma profiles, guiding the selection of targeted therapeutic agents. Such precision-oriented approaches are redefining clinical guidelines, with professional societies increasingly endorsing molecularly informed decision-making. As the pipeline continues to expand, the convergence of pharmacology, diagnostics, and data analytics is poised to accelerate further revolutions in patient care.

Assessing the 2025 US Tariff Shifts on Drug Accessibility and Pricing

The United States’ implementation of revised tariffs in 2025 has introduced new complexities for stakeholders in the primary aldosteronism drug market. With import duties recalibrated across key active pharmaceutical ingredients, manufacturers and distributors have been compelled to reassess supply chain strategies. Imported intermediates necessary for the synthesis of spironolactone, eplerenone, and finerenone now face incremental cost pressures, prompting negotiations for localized sourcing and vertical integration to mitigate margin erosion.

Consequently, price volatility has emerged as a critical concern for payers and healthcare providers. While cost-containment measures and reimbursement policies have endeavored to absorb tariff-induced price increases, the net effect has been a recalibration of contract terms and formulary placements. In parallel, the tariff shifts have incentivized domestic manufacturing investments, with stakeholders exploring partnerships and capacity expansions to secure uninterrupted access. This evolving economic landscape demands agility from industry participants as they navigate tariff-related headwinds and safeguard patient access to essential therapies.

Deep Dive into Molecular, Administration, Therapy Line, Formulation and Channel Dynamics

A nuanced understanding of market segmentation underpins strategic decision-making in the primary aldosteronism space. When viewed through the lens of molecular differentiation, eplerenone emerges as a preferred option for patients requiring a well-tolerated mineralocorticoid receptor antagonist, while finerenone’s heightened receptor potency positions it as a next-generation candidate for those at heightened risk of cardiovascular complications. Spironolactone, with its established clinical track record and cost advantage, continues to maintain a significant footprint, particularly in resource-constrained settings.

Route of administration considerations further inform treatment protocols. Intravenous delivery is typically reserved for acute inpatient scenarios where rapid pharmacodynamic effects are necessary to control severe mineralocorticoid excess. In contrast, oral formulations remain the backbone of chronic management, offering dosing flexibility and ease of administration across diverse care settings. Within the therapeutic continuum, first-line deployment of these agents reflects both clinical guidelines and patient tolerance, while second-line utilization often addresses refractory cases or combination strategies.

Formulation innovation has introduced both extended-release and immediate-release variants. Extended-release options, delivered as capsules or tablets, have been designed to maintain steady plasma concentrations and reduce dosing frequency. Immediate-release presentations, available in suspension and tablet form, allow for dose adjustments and acute titration based on patient response. Distribution channels also shape market dynamics: hospital pharmacies ensure access for inpatient and emergency use, whereas retail settings-whether under large chain franchises or independent community pharmacies-facilitate continuity of care in outpatient environments.

Regional Nuances Shaping Aldosteronism Drug Uptake across Key Markets

Regional demand for primary aldosteronism therapies reflects disparities in diagnostic infrastructure, healthcare funding models, and clinician awareness. In the Americas, market growth is underpinned by robust screening initiatives, high disease awareness, and well-established reimbursement programs that foster uptake of novel agents. Research collaborations between academic centers and commercial entities have accelerated clinical trial enrollment, enabling faster regulatory approvals and early adoption of emerging therapies.

Europe, the Middle East and Africa present a heterogeneous landscape. Western European nations benefit from harmonized regulatory frameworks and public healthcare systems that prioritize cost-effectiveness analyses, supporting the integration of both established and advanced mineralocorticoid receptor antagonists. Conversely, in emerging markets across the Middle East and Africa, limited diagnostic capabilities and budget constraints have tempered adoption rates, although targeted intervention programs and public-private partnerships are beginning to fill critical gaps.

The Asia-Pacific region exhibits another distinctive profile, driven by escalating hypertension prevalence and expanding health insurance coverage in key economies. Local manufacturing initiatives in countries such as India and China are enhancing drug affordability, while regional regulatory authorities increasingly align with international standards to expedite market entry. Collaborative networks among endocrine societies are also fostering clinician education and guideline development, further catalyzing market penetration of both generic and branded therapies.

Competitive Vigor among Leading Players in Aldosteronism Therapeutics

The competitive arena for primary aldosteronism drugs is dominated by a mix of multinational pharmaceutical leaders and specialized biotechs. Originators of spironolactone have navigated patent expiries through lifecycle management strategies, including the launch of novel formulations and strategic licensing agreements. Eplerenone’s stewardship lies with firms that emphasize targeted marketing in cardiovascular and renal specialty channels, leveraging robust clinical evidence to reinforce therapeutic advantages over legacy options.

Finerenone represents a case study in next-generation product introduction. Backed by peer-reviewed trials demonstrating cardiovascular and renal protective benefits, its manufacturer has forged strategic alliances with healthcare systems to support formulary inclusion. Concurrently, a cohort of emerging biotech ventures is advancing pipeline candidates aimed at further enhancing receptor selectivity and reducing off-target hormonal effects. These players often pursue co-development partnerships with established firms to accelerate clinical development and navigate complex regulatory pathways.

Additionally, contract manufacturing organizations and regional generic suppliers have intensified their presence, particularly in high-volume markets. By offering cost-competitive spironolactone and eplerenone generics, they exert downward pressure on pricing while expanding accessibility. Together, these diverse entities create a vibrant competitive ecosystem, with each stakeholder seeking to optimize product differentiation, supply stability, and market share.

Strategic Imperatives for Leaders in the Aldosteronism Drug Sphere

Industry leaders must embrace a multifaceted strategy to capitalize on emerging opportunities in the primary aldosteronism market. First, investment in diagnostic education and early screening programs can drive patient identification and enable timely intervention; collaboration with professional societies and health systems will amplify these initiatives. Second, prioritizing formulation innovation-particularly extended-release and flexible-dose immediate-release options-can enhance patient adherence and differentiate products in crowded portfolios.

In parallel, companies should proactively engage with policymakers and payers to navigate tariff-induced cost dynamics and secure favorable reimbursement pathways. Establishing localized manufacturing or supply partnerships can further mitigate economic pressures and ensure uninterrupted access. Moreover, forging alliances with regional stakeholders-academic centers, biotech innovators, and contract manufacturers-will accelerate pipeline progression and support market expansion in underserved geographies.

Finally, leveraging real-world evidence to demonstrate long-term outcomes and cost-effectiveness will reinforce value propositions. By integrating pharmacoeconomic data into health technology assessments, manufacturers can solidify formulary positioning and foster clinician confidence. Through these concerted actions, industry leaders can not only navigate current complexities but also shape the future standard of care for patients with primary aldosteronism.

Robust Methodological Framework Driving Insightful Analysis

This analysis draws upon a comprehensive, multi-source research framework to ensure depth and reliability. Primary data were obtained through interviews with endocrinologists, cardiologists, and key opinion leaders across major markets. These insights were triangulated with secondary research encompassing peer-reviewed journals, regulatory filings, clinical trial databases, and policy archives.

Market segmentation and competitive dynamics were mapped through a rigorous assessment of company annual reports, financial disclosures, and product registries. Tariff impacts were examined via trade databases and governmental notices, while regional supply chain analyses incorporated shipment records and capacity audits. Quality assurance protocols included cross-validation of quantitative findings and peer review by domain experts to maintain methodological integrity.

Statistical analysis adhered to best practices, employing descriptive analytics for market share estimations and thematic synthesis for qualitative insights. The result is a robust and transparent methodological foundation that underpins the strategic and operational recommendations presented herein, ensuring these insights can guide informed decision-making within the primary aldosteronism therapeutic domain.

Synthesis of Findings and Outlook for Therapeutic Innovation

In synthesizing the data and expert perspectives, it becomes evident that the treatment of primary aldosteronism stands at a transformative juncture. Molecular innovations like finerenone are expanding therapeutic horizons, while improvements in diagnostic precision are redefining patient pathways. Despite economic headwinds introduced by tariff adjustments, strategic supply chain realignment and stakeholder collaboration have maintained drug accessibility and fostered market resilience.

Segmentation and regional insights reveal that tailored approaches-whether through formulation offerings or targeted market entry strategies-are vital to achieving differentiation and sustained growth. Competitive intensity remains high, with originators, generics, and biotechs all vying for share, underscoring the importance of clear value propositions grounded in clinical and economic outcomes.

Looking ahead, those who invest in robust evidence generation, engage proactively with payers, and leverage strategic partnerships will be best positioned to lead the field. The findings outlined in this summary provide a cogent roadmap for stakeholders seeking to navigate the evolving primary aldosteronism landscape and capitalize on opportunities that promise both clinical impact and commercial success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Molecule
    • Eplerenone
    • Finerenone
    • Spironolactone
  • Route Of Administration
    • Intravenous
    • Oral
  • Line Of Therapy
    • First Line
    • Second Line
  • Formulation
    • Extended Release
      • Capsule
      • Tablet
    • Immediate Release
      • Suspension
      • Tablet
  • Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Glenmark Pharmaceuticals Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs Used for Treating Primary Aldosteronism Market, by Molecule
8.1. Introduction
8.2. Eplerenone
8.3. Finerenone
8.4. Spironolactone
9. Drugs Used for Treating Primary Aldosteronism Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Drugs Used for Treating Primary Aldosteronism Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
11. Drugs Used for Treating Primary Aldosteronism Market, by Formulation
11.1. Introduction
11.2. Extended Release
11.2.1. Capsule
11.2.2. Tablet
11.3. Immediate Release
11.3.1. Suspension
11.3.2. Tablet
12. Drugs Used for Treating Primary Aldosteronism Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Retail Pharmacy
12.3.1. Chain Pharmacy
12.3.2. Independent Pharmacy
13. Americas Drugs Used for Treating Primary Aldosteronism Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Drugs Used for Treating Primary Aldosteronism Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.3. Viatris Inc.
16.3.4. Novartis AG
16.3.5. Sun Pharmaceutical Industries Ltd.
16.3.6. Lupin Limited
16.3.7. Dr. Reddy's Laboratories Ltd.
16.3.8. Cipla Limited
16.3.9. Aurobindo Pharma Limited
16.3.10. Glenmark Pharmaceuticals Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET MULTI-CURRENCY
FIGURE 2. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET MULTI-LANGUAGE
FIGURE 3. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EPLERENONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FINERENONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 50. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 52. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 53. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 54. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 55. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 57. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 60. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 98. GERMANY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. GERMANY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 101. GERMANY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 102. GERMANY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 103. GERMANY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 104. GERMANY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. GERMANY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 106. FRANCE DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 107. FRANCE DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. FRANCE DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 109. FRANCE DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 110. FRANCE DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 112. FRANCE DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. FRANCE DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 122. ITALY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 123. ITALY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. ITALY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 125. ITALY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 126. ITALY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 127. ITALY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 128. ITALY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. ITALY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 130. SPAIN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 131. SPAIN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. SPAIN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 133. SPAIN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 134. SPAIN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 136. SPAIN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. SPAIN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 146. SAUDI ARABIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 147. SAUDI ARABIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. SAUDI ARABIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 154. SOUTH AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 155. SOUTH AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SOUTH AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 162. DENMARK DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 163. DENMARK DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. DENMARK DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 165. DENMARK DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 166. DENMARK DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 167. DENMARK DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 168. DENMARK DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. DENMARK DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 178. QATAR DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 179. QATAR DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. QATAR DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 181. QATAR DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 182. QATAR DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 183. QATAR DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 184. QATAR DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. QATAR DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 186. FINLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 187. FINLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. FINLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 189. FINLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 190. FINLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 192. FINLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. FINLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 194. SWEDEN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 195. SWEDEN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. SWEDEN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 210. EGYPT DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 211. EGYPT DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. EGYPT DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 213. EGYPT DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 214. EGYPT DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 215. EGYPT DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 216. EGYPT DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. EGYPT DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 218. TURKEY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 219. TURKEY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. TURKEY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 221. TURKEY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 222. TURKEY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. TURKEY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 226. ISRAEL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 227. ISRAEL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. ISRAEL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 234. NORWAY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 235. NORWAY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. NORWAY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 237. NORWAY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 238. NORWAY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 240. NORWAY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. NORWAY DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 242. POLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 243. POLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. POLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 245. POLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 246. POLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 247. POLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 248. POLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. POLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 250. SWITZERLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 251. SWITZERLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030

Companies Mentioned

The companies profiled in this Drugs Used for Treating Primary Aldosteronism market report include:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Glenmark Pharmaceuticals Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Aldosterone Synthase Inhibitors - Pipeline Insight, 2025 - Product Image

Aldosterone Synthase Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Drugs for Treating Hyperuricemia Market by Drug Class, Route Of Administration, Distribution Channel, Prescription Type - Global Forecast to 2030 - Product Image

Drugs for Treating Hyperuricemia Market by Drug Class, Route Of Administration, Distribution Channel, Prescription Type - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Treating Chronic Myeloid Leukemia by Phase Market by Treatment Type, Phase, Treatment Setting, Patient Age Group - Global Forecast to 2030 - Product Image

Treating Chronic Myeloid Leukemia by Phase Market by Treatment Type, Phase, Treatment Setting, Patient Age Group - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 207 Pages
  • Global
From
Topical Drugs Market Size, Share & Trends Analysis Report By Route Of Administration, By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Topical Drugs Market Size, Share & Trends Analysis Report By Route Of Administration, By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.